Products

^PrFOSAMAX^®

(alendronate sodium tablets)
(alendronate sodium oral solution)

Disclaimer

Original Notice of Compliance (NoC)

December 18, 1995

Therapeutic / Pharmacological Classification

Bone Metabolism Regulator

Product Monograph / Prescribing Information / Product Information

Date of Revision: February 23, 2007 (1081-a,2,07)
File name: FOSAMAX_1081-a_2_07-E.pdf
File size: 620 KB

CONSUMER INFORMATION

Date of Revision: February 23, 2007 (1081-a,2,07)
File name: FOSAMAX_1081-a_2_07_CI-E.pdf
File size: 131 KB

This file is presented in PDF format. This software is available at no charge through the Adobe Web site. Get Adobe Reader

DISCLAIMER
The contents of this site, including but not limited to Merck Frosst product information and product monographs, are for informational purposes only and are intended solely for residents of Canada, and are not intended, nor should they be used, as a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician, pharmacist or other qualified health care provider with any questions you may have regarding a medical condition.

® Registered Trademark of Merck & Co., Inc. Used under license.

Printer friendly

Email a friend

This site is for residents of Canada. / This site was updated on May 2, 2008.

PrFOSAMAX®

(alendronate sodium tablets)(alendronate sodium oral solution)